CareDx reports incentive payment pursuant to Nasdaq Listing Rule 5635(c)(4)

CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company – a leading precision medicine company focused on discovering, developing and commercializing clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that on September 12, 2024, CareDx has granted Keith S. Kennedy, newly appointed Chief Operating Officer of CareDx, an option to purchase 100,651 shares of CareDx common stock (the “Kennedy Inducement Option”) and 70,101 restricted stock units (the “Kennedy Inducement RSUs”) and an option to purchase 75,488 shares of CareDx common stock (the “Meng Inducement Option” and together with the Kennedy Inducement Option, the “Inducement Options”) and 52,576 restricted stock units (the “Meng Inducement RSUs” and together with the Kennedy Inducement RSUs (the “Inducement RSUs”) to Jessica Meng, the newly appointed Chief Commercial Officer of CareDx. The Inducement Options and the Inducement RSUs were approved by the Compensation and Human Capital Committee of CareDx's Board of Directors on September 6, 2024 and were a material incentive for Mr. Kennedy's and Ms. Meng's respective employment with CareDx in accordance with Nasdaq Listing Rule 5635(c)(4).

The Incentive Options have an exercise price of $29.43 and will vest over a four-year period, with 25% of the total number of shares subject to the Incentive Options vesting on September 12, 2025, the one-year anniversary of the commencement of Kennedy's and Meng's employment with CareDx, and 1/48 of the total number of shares subject to the Incentive Options vesting at the end of each calendar month thereafter, subject to Kennedy's and Meng's respective continuation of service with CareDx on each vesting date. The Incentive RSUs will vest in four equal annual installments beginning on September 12, 2025, the one-year anniversary of the commencement of Kennedy's and Meng's employment with CareDx, subject to Kennedy's and Meng's respective continuation of service with CareDx on each vesting date.